Anti-mycobactrial antibiotics: Select all that apply

Mycobacterium tuberculosis is a slow-growing, acid-fast bacillus characterized by a unique, waxy cell wall rich in mycolic acids. Treatment of mycobacterial infections requires specialized antibiotics that can penetrate this complex wall and act over long periods. Combination therapy is mandatory to prevent the emergence of multidrug-resistant strains. These drugs target specific biosynthetic pathways unique to the Mycobacterium genus. Rationale: A. Isoniazid (INH) is a primary anti-mycobacterial agent and a prodrug that inhibits the synthesis of mycolic acids, essential components of the mycobacterial cell wall. It is highly bactericidal against rapidly dividing organisms. Patients taking INH must be monitored for hepatotoxicity and peripheral neuropathy, often requiring pyridoxine (vitamin B6) supplementation for nerve protection. B. Ethambutol is a first-line anti-mycobacterial antibiotic that works by inhibiting arabinosyl transferase, an enzyme involved in cell wall synthesis. It is bacteriostatic and helps prevent the development of resistance to other drugs in the regimen. A key clinical consideration for ethambutol is the risk of optic neuritis, necessitating regular vision testing during treatment. C. Bacitracin is a polypeptide antibiotic used primarily for topical skin infections caused by Gram-positive bacteria. It inhibits bacterial cell wall synthesis by interfering with dephosphorylation but is not effective against the unique lipid-rich wall of mycobacteria. It is not part of any clinical regimen for tuberculosis or other mycobacterial diseases. D. This is correct because both isoniazid and ethambutol are classified as anti-mycobacterial agents used in the standard RIPE (Rifampin, Isoniazid, Pyrazinamide, Ethambutol) regimen. These drugs work synergistically to eradicate the pathogen from different metabolic states. Their inclusion in the treatment protocol is essential for successful patient outcomes in tuberculosis cases. E. This choice is incorrect because it includes bacitracin, which has no activity against mycobacteria. While isoniazid is a cornerstone of anti-tubercular therapy, bacitracin's spectrum of activity is limited to superficial cutaneous or ophthalmic infections. Relying on bacitracin for mycobacterial control would lead to treatment failure and disease progression.